Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 351

1.

Use of glycoprotein IIb/IIIa inhibitors in invasively-treated patients with non-ST elevation acute coronary syndrome.

De Servi S, Mariani M, Vandoni P, Dellavalle A, Politi A, Poletti F, Bonizzoni E, Leoncinie M; Registro Osservazionale Angina Instabile (ROSAI-2) Investigators.

J Cardiovasc Med (Hagerstown). 2006 Mar;7(3):159-65.

PMID:
16645379
[PubMed - indexed for MEDLINE]
2.

Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE).

Tricoci P, Peterson ED, Chen AY, Newby LK, Harrington RA, Greenbaum AB, Cannon CP, Gibson CM, Hoekstra JW, Pollack CV Jr, Ohman EM, Gibler WB, Roe MT.

Am J Cardiol. 2007 May 15;99(10):1389-93. Epub 2007 Mar 26.

PMID:
17493466
[PubMed - indexed for MEDLINE]
3.

Treatment modalities of non-ST-elevation acute coronary syndromes in the real world. Results of the prospective R.OS.A.I.-2 registry.

Registro Osservazionale Angina Instabile Investigators.

Ital Heart J. 2003 Nov;4(11):782-90.

PMID:
14699708
[PubMed - indexed for MEDLINE]
4.

Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial.

Stone GW, Bertrand ME, Moses JW, Ohman EM, Lincoff AM, Ware JH, Pocock SJ, McLaurin BT, Cox DA, Jafar MZ, Chandna H, Hartmann F, Leisch F, Strasser RH, Desaga M, Stuckey TD, Zelman RB, Lieber IH, Cohen DJ, Mehran R, White HD; ACUITY Investigators.

JAMA. 2007 Feb 14;297(6):591-602.

PMID:
17299194
[PubMed - indexed for MEDLINE]
5.

Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention.

Boersma E, Akkerhuis KM, Théroux P, Califf RM, Topol EJ, Simoons ML.

Circulation. 1999 Nov 16;100(20):2045-8. Review.

PMID:
10562258
[PubMed - indexed for MEDLINE]
Free Article
6.

The impact of GP IIb/IIIa inhibitors during primary percutaneous coronary intervention in acute myocardial infarction patients.

Lavi S, Gruberg L, Kapeliovich M, Hammerman H, Boulos M, Grenadier E, Aronson D, Markiewicz W, Beyar R.

J Invasive Cardiol. 2005 Jun;17(6):296-9.

PMID:
16003002
[PubMed - indexed for MEDLINE]
7.

Frequency and outcomes of provisional glycoprotein IIb/IIIa blockade in patients receiving bivalirudin during percutaneous coronary intervention.

Feldman DN, Wong SC, Bergman G, Minutello RM.

J Invasive Cardiol. 2009 Jun;21(6):258-63.

PMID:
19494400
[PubMed - indexed for MEDLINE]
Free Article
8.

Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial.

Rajagopal V, Lincoff AM, Cohen DJ, Gurm HS, Hu T, Desmet WJ, Kleiman NS, Bittl JA, Feit F, Topol EJ.

Am Heart J. 2006 Jul;152(1):149-54.

PMID:
16824845
[PubMed - indexed for MEDLINE]
9.

The role of risk stratification in the decision to provide upstream versus selective glycoprotein IIb/IIIa inhibitors for acute coronary syndromes: a cost-effectiveness analysis.

Glaser R, Glick HA, Herrmann HC, Kimmel SE.

J Am Coll Cardiol. 2006 Feb 7;47(3):529-37. Epub 2006 Jan 18.

PMID:
16458131
[PubMed - indexed for MEDLINE]
Free Article
11.

[The clinical use of the GPIIb/IIIa inhibitors eptifibatide and tirofiban in the treatment of acute coronary syndromes of the "non-ST elevation" type].

Galli M, Maggioni AP, Vassanelli C, Tavazzi L.

Ital Heart J Suppl. 2000 Feb;1(2):202-11. Review. Italian.

PMID:
10731377
[PubMed - indexed for MEDLINE]
12.

Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials.

Tricoci P, Newby LK, Hasselblad V, Kong DF, Giugliano RP, White HD, Théroux P, Stone GW, Moliterno DJ, Van de Werf F, Armstrong PW, Prabhakaran D, Rasoul S, Bolognese L, Durand E, Braunwald E, Califf RM, Harrington RA.

Circ Cardiovasc Qual Outcomes. 2011 Jul;4(4):448-58. doi: 10.1161/CIRCOUTCOMES.110.960294. Epub 2011 Jun 28. Review.

PMID:
21712522
[PubMed - indexed for MEDLINE]
Free Article
14.

Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.

Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, Neumann FJ, Robertson DH, DeLucca PT, DiBattiste PM, Gibson CM, Braunwald E; TACTICS (Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy)--Thrombolysis in Myocardial Infarction 18 Investigators.

N Engl J Med. 2001 Jun 21;344(25):1879-87.

PMID:
11419424
[PubMed - indexed for MEDLINE]
Free Article
15.

A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials.

Gurm HS, Tamhane U, Meier P, Grossman PM, Chetcuti S, Bates ER.

Circ Cardiovasc Interv. 2009 Jun;2(3):230-6. doi: 10.1161/CIRCINTERVENTIONS.108.847996. Epub 2009 Apr 21.

PMID:
20031720
[PubMed - indexed for MEDLINE]
Free Article
16.

Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.

Ferguson JJ, Antman EM, Bates ER, Cohen M, Every NR, Harrington RA, Pepine CJ, Theroux P; NICE-3 Investigators.

Am Heart J. 2003 Oct;146(4):628-34.

PMID:
14564315
[PubMed - indexed for MEDLINE]
17.

Characteristics, treatment and outcome of patients with non-ST-elevation acute coronary syndromes and multivessel coronary artery disease: observations from PURSUIT (platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrelin therapy).

Breeman A, Mercado N, Lenzen M, van den Brand MM, Harrington RA, Califf RM, Topol EJ, Simoons ML, Boersma E; PURSUIT Investigators.

Cardiology. 2002;98(4):195-201.

PMID:
12566649
[PubMed - indexed for MEDLINE]
18.

Glycoprotein IIb/IIIa inhibitors during rescue percutaneous coronary intervention in acute myocardial infarction.

Gruberg L, Suleiman M, Kapeliovich M, Hammerman H, Grenadier E, Boulus M, Amikam S, Markiewicz W, Beyar R.

J Invasive Cardiol. 2006 Feb;18(2):59-62.

PMID:
16446517
[PubMed - indexed for MEDLINE]
19.

Impact of preprocedural TIMI flow on myocardial perfusion, distal embolization and mortality in patients with ST-segment elevation myocardial infarction treated by primary angioplasty and glycoprotein IIb/IIIa inhibitors.

Maioli M, Zeymer U, van 't Hof AW, Gibson CM, Dudek D, Bellandi F, Noc M, Secco GG, Zorman S, Gabriel HM, Emre A, Cutlip D, Rakowski T, Gyongyosi M, Huber K, De Luca G; EGYPT Cooperation.

J Invasive Cardiol. 2012 Jul;24(7):324-7.

PMID:
22781470
[PubMed - indexed for MEDLINE]
Free Article
20.

Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.

Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Kereiakes DJ, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ; REPLACE-2 Investigators.

JAMA. 2003 Feb 19;289(7):853-63. Erratum in: JAMA. 2003 Apr 2;289(13):1638.

PMID:
12588269
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk